Clinical investigation of the pharmacokinetics of therapeutic proteins - Scientific guideline
HumanScientific guidelines
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
This document underlines the specific problems related to the pharmacokinetics of protein products that need careful consideration during drug development.
Keywords: Therapeutic proteins, pharmacokinetics
Current effective version
Related content
- Clinical efficacy and safety: clinical pharmacology and pharmacokinetics
- Directive 2001/83/EC
Questions and answers: Positions on specific questions addressed to the Pharmacokinetics Working Party- Evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function
- Evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function
- ICH E3 Structure and content of clinical study reports
- ICH E6 (R1) Good clinical practice
- ICH E8 General considerations for clinical trials
- ICH S6 (R1) Preclinical safety evaluation of biotechnology-derived pharmaceuticals
- Investigation of bioequivalence
- Investigation of drug interactions
- Pharmacokinetic studies in man